Sesen slams brakes on phase 3 bladder cancer program to save cash as it looks for off-ramp

Sesen Bio is pumping the brakes on its phase 3 bladder cancer program. After weighing up what it will take to get Vicineum to market, the biotech has paused clinical development in the U.S. to preserve the cash that could be key to its exit.